-
Something wrong with this record ?
The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: Effects in human colorectal HCT116 TP53(+/+), TP53(+/-) and TP53(-/-) cells
AJ. Willis, R. Indra, LE. Wohak, O. Sozeri, K. Feser, I. Mrizova, DH. Phillips, M. Stiborova, VM. Arlt,
Language English Country Ireland
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- DNA Adducts metabolism MeSH
- Benzo(a)pyrene pharmacokinetics pharmacology MeSH
- Cisplatin pharmacology MeSH
- Cytochrome P-450 CYP1A1 biosynthesis metabolism MeSH
- Cytochrome P-450 CYP3A biosynthesis metabolism MeSH
- Ellipticines pharmacokinetics pharmacology MeSH
- Enzyme Induction drug effects MeSH
- Etoposide pharmacology MeSH
- Genes, p53 MeSH
- HCT116 Cells MeSH
- Carcinogens pharmacokinetics pharmacology MeSH
- Colorectal Neoplasms drug therapy genetics metabolism pathology MeSH
- Humans MeSH
- Activation, Metabolic MeSH
- Tumor Suppressor Protein p53 deficiency genetics metabolism MeSH
- DNA Damage MeSH
- Cell Survival drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Polycyclic aromatic hydrocarbons such as benzo[a]pyrene (BaP) can induce cytochrome P450 1A1 (CYP1A1) via a p53-dependent mechanism. The effect of different p53-activating chemotherapeutic drugs on CYP1A1 expression, and the resultant effect on BaP metabolism, was investigated in a panel of isogenic human colorectal HCT116 cells with differing TP53 status. Cells that were TP53(+/+), TP53(+/-) or TP53(-/-) were treated for up to 48 h with 60 μM cisplatin, 50 μM etoposide or 5 μM ellipticine, each of which caused high p53 induction at moderate cytotoxicity (60-80% cell viability). We found that etoposide and ellipticine induced CYP1A1 in TP53(+/+) cells but not in TP53(-/-) cells, demonstrating that the mechanism of CYP1A1 induction is p53-dependent; cisplatin had no such effect. Co-incubation experiments with the drugs and 2.5 μM BaP showed that: (i) etoposide increased CYP1A1 expression in TP53(+/+) cells, and to a lesser extent in TP53(-/-) cells, compared to cells treated with BaP alone; (ii) ellipticine decreased CYP1A1 expression in TP53(+/+) cells in BaP co-incubations; and (iii) cisplatin did not affect BaP-mediated CYP1A1 expression. Further, whereas cisplatin and etoposide had virtually no influence on CYP1A1-catalysed BaP metabolism, ellipticine treatment strongly inhibited BaP bioactivation. Our results indicate that the underlying mechanisms whereby etoposide and ellipticine regulate CYP1A1 expression must be different and may not be linked to p53 activation alone. These results could be relevant for smokers, who are exposed to increased levels of BaP, when prescribing chemotherapeutic drugs. Beside gene-environment interactions, more considerations should be given to potential drug-environment interactions during chemotherapy.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000905
- 003
- CZ-PrNML
- 005
- 20190121113320.0
- 007
- ta
- 008
- 190107s2018 ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.tox.2018.02.006 $2 doi
- 035 __
- $a (PubMed)29471073
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Willis, Alexandra J $u Department of Analytical, Environmental and Forensic Sciences, MRC-PHE Centre for Environment and Health, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom.
- 245 14
- $a The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: Effects in human colorectal HCT116 TP53(+/+), TP53(+/-) and TP53(-/-) cells / $c AJ. Willis, R. Indra, LE. Wohak, O. Sozeri, K. Feser, I. Mrizova, DH. Phillips, M. Stiborova, VM. Arlt,
- 520 9_
- $a Polycyclic aromatic hydrocarbons such as benzo[a]pyrene (BaP) can induce cytochrome P450 1A1 (CYP1A1) via a p53-dependent mechanism. The effect of different p53-activating chemotherapeutic drugs on CYP1A1 expression, and the resultant effect on BaP metabolism, was investigated in a panel of isogenic human colorectal HCT116 cells with differing TP53 status. Cells that were TP53(+/+), TP53(+/-) or TP53(-/-) were treated for up to 48 h with 60 μM cisplatin, 50 μM etoposide or 5 μM ellipticine, each of which caused high p53 induction at moderate cytotoxicity (60-80% cell viability). We found that etoposide and ellipticine induced CYP1A1 in TP53(+/+) cells but not in TP53(-/-) cells, demonstrating that the mechanism of CYP1A1 induction is p53-dependent; cisplatin had no such effect. Co-incubation experiments with the drugs and 2.5 μM BaP showed that: (i) etoposide increased CYP1A1 expression in TP53(+/+) cells, and to a lesser extent in TP53(-/-) cells, compared to cells treated with BaP alone; (ii) ellipticine decreased CYP1A1 expression in TP53(+/+) cells in BaP co-incubations; and (iii) cisplatin did not affect BaP-mediated CYP1A1 expression. Further, whereas cisplatin and etoposide had virtually no influence on CYP1A1-catalysed BaP metabolism, ellipticine treatment strongly inhibited BaP bioactivation. Our results indicate that the underlying mechanisms whereby etoposide and ellipticine regulate CYP1A1 expression must be different and may not be linked to p53 activation alone. These results could be relevant for smokers, who are exposed to increased levels of BaP, when prescribing chemotherapeutic drugs. Beside gene-environment interactions, more considerations should be given to potential drug-environment interactions during chemotherapy.
- 650 _2
- $a metabolická aktivace $7 D065767
- 650 _2
- $a benzopyren $x farmakokinetika $x farmakologie $7 D001564
- 650 _2
- $a karcinogeny $x farmakokinetika $x farmakologie $7 D002273
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a cisplatina $x farmakologie $7 D002945
- 650 _2
- $a kolorektální nádory $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D015179
- 650 _2
- $a cytochrom P-450 CYP1A1 $x biosyntéza $x metabolismus $7 D019363
- 650 _2
- $a cytochrom P-450 CYP3A $x biosyntéza $x metabolismus $7 D051544
- 650 _2
- $a adukty DNA $x metabolismus $7 D018736
- 650 _2
- $a poškození DNA $7 D004249
- 650 _2
- $a elipticiny $x farmakokinetika $x farmakologie $7 D004611
- 650 _2
- $a enzymová indukce $x účinky léků $7 D004790
- 650 _2
- $a etoposid $x farmakologie $7 D005047
- 650 _2
- $a geny p53 $7 D016158
- 650 _2
- $a HCT116 buňky $7 D045325
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádorový supresorový protein p53 $x nedostatek $x genetika $x metabolismus $7 D016159
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Indra, Radek $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, Czech Republic.
- 700 1_
- $a Wohak, Laura E $u Department of Analytical, Environmental and Forensic Sciences, MRC-PHE Centre for Environment and Health, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom.
- 700 1_
- $a Sozeri, Osman $u Department of Analytical, Environmental and Forensic Sciences, MRC-PHE Centre for Environment and Health, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom.
- 700 1_
- $a Feser, Kerstin $u Department of Analytical, Environmental and Forensic Sciences, MRC-PHE Centre for Environment and Health, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom.
- 700 1_
- $a Mrizova, Iveta $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, Czech Republic.
- 700 1_
- $a Phillips, David H $u Department of Analytical, Environmental and Forensic Sciences, MRC-PHE Centre for Environment and Health, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom; NIHR Health Protection Research Unit in Health Impact of Environmental Hazards at King's College London in partnership with Public Health England, London, 150 Stamford Street, London SE1 9NH, United Kingdom.
- 700 1_
- $a Stiborova, Marie $u Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, Czech Republic.
- 700 1_
- $a Arlt, Volker M $u Department of Analytical, Environmental and Forensic Sciences, MRC-PHE Centre for Environment and Health, King's College London, 150 Stamford Street, London SE1 9NH, United Kingdom; NIHR Health Protection Research Unit in Health Impact of Environmental Hazards at King's College London in partnership with Public Health England, London, 150 Stamford Street, London SE1 9NH, United Kingdom. Electronic address: volker.arlt@kcl.ac.uk.
- 773 0_
- $w MED00004533 $t Toxicology $x 1879-3185 $g Roč. 398-399, č. - (2018), s. 1-12
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29471073 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20190121113538 $b ABA008
- 999 __
- $a ok $b bmc $g 1364882 $s 1039028
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 398-399 $c - $d 1-12 $e 20180219 $i 1879-3185 $m Toxicology $n Toxicology $x MED00004533
- LZP __
- $a Pubmed-20190107